MYGN
MYRIAD GENETICS INC
Next earnings Aug 3, 2026 (after close) · consensus $-0.06 EPS, $210M rev
Last earnings +1.8% on 2026-05-05
$5.88
▲ +8.29%$5.88▲ +20.99%
over 1Y
L $3.55EODHDH $8.18
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.3%
1W+30.7%
1M+49.6%
3M+37.4%
YTD-4.2%
1Y+21.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Hold
Conservative balance sheet (liabilities/equity 0.92x); but revenue declined -1.6% YoY.
Revenue (FY2025) $825M · FY2025
MYRIAD GENETICS INC shows $825M in FY2025 revenue (-1.6% YoY), a -44.4% net margin, and -99.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $691M | $678M | $753M | $838M | $825M |
| Gross profit | — | $476M | $517M | $585M | $577M |
| Operating income | -$191M | -$141M | -$257M | -$124M | -$387M |
| Net income | -$27.2M | -$112M | -$263M | -$127M | -$366M |
| Diluted EPS | -$0.35 | -$1.39 | -$3.18 | -$1.41 | -$3.95 |
| Net margin | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$520M
EV / EBITDA—
EV / Sales0.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-66.5%
FCF yield-7.9%
Quality & risk
ROIC (est.)-62.7%
Free cash flow-$43.5M
Total debt$120M
Net cash$29.7M
Altman Z-Score-1.55 distress
Piotroski F-Score5/9
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-23
- 8-K Officer / director change2026-06-04
- 10-Q Quarterly report2026-05-06
- 8-K Earnings results2026-05-05
- DEF 14A Proxy statement2026-04-14
- S-3 Shelf registration (potential raise)2026-02-24
- 10-K Annual report2026-02-24
- 8-K Earnings results2026-02-23
- 8-K Earnings results2026-01-12
Recent filings
all on EDGAR ↗4Period ending 2026-06-232026-06-23open ↗8-KPeriod ending 2026-06-172026-06-23open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-082026-06-09open ↗144Filing2026-06-08open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗
Frequently asked
- Is MYRIAD GENETICS INC (MYGN) a buy?
- MYGN currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.92x); but revenue declined -1.6% YoY.
- What is MYRIAD GENETICS INC's quality score?
- MYGN scores 48.76470588235294/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000899923, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 6:05:27 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.